Voyager Therapeutics, Inc. (VYGR)
Nasdaq · Healthcare · Biotechnology
$2.46+0.41%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $152M
- 52-week range
- $2.39 – $5.55
- 52-week change
- −48.20%
- EPS (trailing)
- −$1.81
- Analyst rating
- 1.0 Strong buy
- Next earnings
- Nov 9, 2026
Fiscal year to Dec 2025
- Revenue
- $40.4M (−49.53%)
- Net income
- −$120M
- Operating margin
- −326.5%
- Diluted EPS
- −$2.04
- Free cash flow
- −$135M
From the company’s annual report on SEC EDGAR.
About Voyager Therapeutics, Inc.
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
Headquarters: Lexington, United States · 141 employees · voyagertherapeutics.com